Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk's Oral Rybelsus Priced On Par With Injectable GLP-1s, But Big Discounts May Be Needed

Executive Summary

A 30-day supply of the first oral GLP-1 agonist will cost $772.43 in the US, similar to the injectable version but steeper than oral diabetes medicines. Deep discounts may be needed to secure market access.

You may also be interested in...



Lilly Aims For Earlier Treatment With Novel Diabetes Drugs

Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.

Novo Nordisk Pays $1.80bn To Buy Emisphere

The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.

Lilly Saw Pandemic-Related Benefits In Q1, Expects Headwinds Long Term

The pharma saw a $250m revenue increase due to inventory stockpiling and early prescription renewals, but its therapies outside cancer and diabetes may suffer in the coming quarters due to COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125897

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel